BPMC - Blueprint Medicines Corporation Stock Trading

Blueprint Medicines Reports First Quarter 2021 Financial Results -- 7 research- and clinical-stage programs highlighted at AACR, including recently nominated development candidate with best-in-class potential targeting CDK2 -- -- GAVRETO® (pralsetinib) becomes the first...

Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021 PR Newswire CAMBRIDGE, Mass. , April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference c...

While the market is hitting all-time highs, shares of the Nasdaq Biotechnology ETF (NASDAQ: IBB) are trading essentially flat year-to-date, down just over 15% from their peak. Down 11% since the beginning of the year, but up just less than fivefold over the past five years , Bluep...